Platinum open access journal
pISSN 2466-0493 eISSN 2466-054X
Indexed in MEDLINE, SCIE, Scopus, DOAJ and more
    Korean J Urol. 2009 Jul;50(7):642-648. Korean.
    Published online Jul 20, 2009.
    https://doi.org/10.4111/kju.2009.50.7.642
    Copyright © The Korean Urological Association, 2009
    Original Article

    Plasma Insulin-Like Growth Factor-1 (IGF-1), IGF-Binding Protein-3, and the Risk of Prostate Cancer: A Matched Case-Control Study in a Korean Population

    Jeong Hyun Kim, Kwan Jin Park,1 Jung-Bum Bae,1 Woon Geol Yeo,1 Seok-Soo Byun,1 and Eun Sik Lee1
      • Department of Urology, Kangwon National University College of Medicine, Chuncheon, Korea.
      • 1Department of Urology, Seoul National University College of Medicine, Seoul, Korea.
    • Correspondence to: Eun Sik Lee. Department of Urology, Seoul National University College of Medicine, 28, Yongon-dong, Chongno-gu, Seoul 110-744, Korea. TEL: 02-2072-2915, FAX: 02-742-4665, Email: eslee@snu.ac.kr
    Received January 22, 2009; Accepted June 15, 2009.

    Abstract

    Purpose

    Conflicting results have been reported for western populations on associations of serum insulin-like growth factor I (IGF-I) and major IGF-binding protein-3 (IGFBP-3) with the risk of prostate cancer. However, few data have been available for oriental populations. We undertook a matched case-control study in a low-risk Korean population to extend our knowledge about potential associations.

    Materials and Methods

    Serum IGF-I and IGFBP-3 levels were determined for 330 men (165 cases and 165 healthy age-matched controls). Conditional logistic regression was used to estimate the odds ratio (OR) and 95% confidence interval (CI) for the association between plasma IGF levels and prostate cancer. We also investigated the potential influence of the associations according to clinical risk for advanced disease at diagnosis.

    Results

    We noted that the risks of prostate cancer were unrelated to the IGF-1 level and IGF-I/IGFBP-3 molar ratio. In contrast, a strong inverse association was observed between IGFBP-3 levels and the risk for prostate cancer. Men in the highest quartile of IGFBP-3 levels had a 71% reduced risk of prostate cancer compared with men in the lowest quartile (OR=0.29, 95% CI: 0.11-0.64, Ptrend<0.001). Subgroup analysis revealed a significant inverse association between plasma IGFBP-3 and the likelihood of a high risk prostate cancer.

    Conclusions

    Plasma IGFBP-3 levels were inversely associated with the risk of prostate cancer and the likelihood for high-risk disease, suggesting that IGFBP-3 plays a protective role against prostate cancer in the Korean population.

    Keywords
    Prostatic neoplasms; Insulin-like growth factor I; Insulin-like growth factor binding protein 3

    Tables

    Table 1
    Selected characteristics of cases with prostate cancer and of matched controls in a Korean population

    Table 2
    Mean plasma IGF-1 and IGFBP-3 concentrations in prostate cancer cases and matched controls in a selected Korean population

    Table 3
    The risk of prostate cancer in relation to plasma levels of IGF-1, IGFBP-3, and their molar ratio

    Table 4
    Odds ratios (OR) and 95% confidence intervals (CI) for prostate cancer according to the plasma levels of IGF-1, IGFBP-3, and the molar ratio of IGF-1/IGFBP-3 by the dichotomized clinical risk for advanced disease

    Notes

    This study was supported by the research grant of the Seoul National University Hospital (04-2005-056).

    References

      1. Fürstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol 2002;3:298–302.
      1. Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer 1992;65:311–320.
      1. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasmainsulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;79:63–66.
      1. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997;76:1115–1118.
      1. Leal SM, Liu Q, Huang SS, Huang JS. The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor. J Biol Chem 1997;72:20572–20576.
      1. Schedlich LJ, Le Page SL, Firth SM, Briggs LJ, Jans DA, Baxter RC. Nuclear import of insulin-like growth factor-inding protein-3 and -5 is mediated by the importin beta subunit. J Biol Chem 2000;275:23462–23470.
      1. Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM, et al. Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis. J Biol Chem 2000;275:33607–33613.
      1. Boyle BJ, Zhao XY, Cohen P, Feldman D. Insulin-like growth factor binding protein-3 mediates 1 alpha, 25-dihydroxyvitamin D(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 2001;165:1319–1324.
      1. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995;377:646–649.
      1. Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J, et al. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 2001;10:421–427.
      1. Stattin P, Bylund A, Rinaldi S, Biessy C, Déchaud H, Stenman UH, et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000;92:1910–1917.
      1. Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB. Baltimore Longitudinal Study on Aging. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 2000;85:4258–4265.
      1. Wolk A, Mantzoros CS, Andersson SO, Bergström R, Signorello LB, Lagiou P, et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998;90:911–915.
      1. Severi G, Morris HA, MacInnis RJ, English DR, Tilley WD, Hopper JL, et al. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:1137–1141.
      1. Chen C, Lewis SK, Voigt L, Fitzpatrick A, Plymate SR, Weiss NS. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer 2005;103:76–84.
      1. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346–1353.
      1. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–974.
      1. Wang L, Habuchi T, Tsuchiya N, Mitsumori K, Ohyama C, Sato K, et al. Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Res 2003;63:4407–4411.
      1. Moon JW, Chang YS, Ahn CW, Yoo KN, Shin JH, Kong JH, et al. Promoter -202 A/C polymorphism of insulin-like growth factor binding protein-3 gene and non-small cell lung cancer risk. Int J Cancer 2006;118:353–356.
      1. Shariat SF, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J, et al. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol 2002;20:833–841.
      1. Kim YJ, Chang IH, Gil MC, Hong SK, Byun SS, Lee SE. Concordance of Gleason scores between prostate needle biopsy and radical prostatectomy specimens according to the number of biopsy cores. Korean J Urol 2006;47:482–488.
      1. Chung JS, Han BK, Jeong SJ, Hong SK, Byun SS, Choe G, et al. Pathologic outcome of unilateral low risk prostate cancers on multicore prostate biopsy after radical prostatectomy. Korean J Urol 2008;49:874–878.
      1. Yu H, Mistry J, Nicar MJ, Khosravi MJ, Diamandis A, van Doorn J, et al. Insulin-like growth factors (IGF-I, free IGF-I and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation. Clin Lab Anal 1999;13:166–172.
      1. Goodman-Gruen D, Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. Am J Epidemiol 1997;145:970–976.
    Cited by
    Scopus 1
    MeSH Terms
    Case-Control Studies
    Humans
    Insulin-Like Growth Factor Binding Protein 3
    Insulin-Like Growth Factor I
    Logistic Models
    Male
    Molar
    Odds Ratio
    Plasma
    Prostate
    Prostatic Neoplasms
    Metrics
    Share
    Tables
    slide
    slide
    slide
    slide

    1 / 4

    PERMALINK